The Smart(est) Choice for Dual Antiplatelet Therapy Is a Patient-Directed One
JAMA Cardiol
.
2022 Nov 1;7(11):1109.
doi: 10.1001/jamacardio.2022.3219.
Authors
Ajay J Kirtane
1
2
,
Roxana Mehran
3
2
Affiliations
1
Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York.
2
Associate Editor, JAMA Cardiology.
3
Icahn School of Medicine at Mount, and the Cardiovascular Research Foundation, New York, New York.
PMID:
36169952
DOI:
10.1001/jamacardio.2022.3219
No abstract available
Publication types
Editorial
Comment
MeSH terms
Clopidogrel
Dual Anti-Platelet Therapy
Humans
Platelet Aggregation Inhibitors* / therapeutic use
Ticlopidine*
Substances
Platelet Aggregation Inhibitors
Clopidogrel
Ticlopidine